ArticleJournal of infection prevention2024
SARS-CoV-2 seroprevalence screening study of a children's hospital health care workers.
Article in Journal of infection prevention, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Health care workers (HCWs) are front line responders to the COVID-19 pandemic, but limited data is available for pediatric HCWs, as the research response has largely focused on adult patients and medical personnel that treat these patients. Methods: We conducted a cross-sectional study of SARS-CoV-2 seroprevalence and risk factors in HCWs at a Children's Hospital in CO, USA from September 2020 to April 2021. Pediatric HCWs were defined as clinical care providers and administrative staff. Seroprevalence was determined using the Epitope SARS-CoV-2 anti-Nucleocapsid IgG assay (San Diego, CA) and the Euroimmun SARS-CoV-2 anti-Spike Protein IgG assay. Risk factors and vaccination status were assessed via questionnaire. Results: Overall, 110 HCWs were enrolled, 79 subjects were positive for anti-S antibodies and negative for anti-N antibodies, indicating COVID-19 vaccination. 31 subjects had neither anti-N or anti-S antibodies, indicating no exposure to SARS-CoV-2 and no vaccination. 3/110 had a nucleocapsid serology consistent with a SARS-CoV-2 prior infection. Seroprevalence was observed at 2.7%. It was noted that asthma requiring medication was associated with positive serostatus. Conclusions: During the winter 2020/21, SARS-CoV-2, we found a 2.7% seroprevalence of pediatric HCW at a children's hospital in Colorado. We compared this with publicly available seroprevalence data for seroprevalence rates of pediatric HCWs globally. This suggests that this specific children's hospital COVID-19 personal protective equipment (PPE) and infection control guidelines were effective in limiting SARS-CoV-2 in hospital transmission at the children's hospital prior to the presence of the Delta variant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.